MD3962455T2 - Compoziție farmaceutică nouă pentru livrare de medicamente - Google Patents
Compoziție farmaceutică nouă pentru livrare de medicamenteInfo
- Publication number
- MD3962455T2 MD3962455T2 MDE20220282T MDE20220282T MD3962455T2 MD 3962455 T2 MD3962455 T2 MD 3962455T2 MD E20220282 T MDE20220282 T MD E20220282T MD E20220282 T MDE20220282 T MD E20220282T MD 3962455 T2 MD3962455 T2 MD 3962455T2
- Authority
- MD
- Moldova
- Prior art keywords
- pharmaceutically acceptable
- compositions
- drug delivery
- nasal
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Abstract
Conform invenţiei, este furnizată o compoziţie farmaceutic acceptabilă care este, de preferinţă, sub formă de pulbere uscată, cuprinzând un amestec de: (a) o cantitate de dozare farmacologică eficientă de cel puţin un compus activ farmaceutic; şi (b) un material purtător acceptabil farmaceutic, care material purtător cuprinde o combinaţie de dizaharidă şi un material polimeric. Compoziţiile sunt adecvate, de exemplu, pentru eliberarea de medicamente transmucoase, incluzând eliberarea sublinguală şi nazală. In cazul administrării nazale, respectivele compoziţii pot fi încărcate în aplicatoare nazale cu utilizare unică sau multiplă. Purtătorii acceptabili farmaceutic preferaţi în această privinţă includ lactoză sau trehaloză şi dextrine (de exemplu, citodextrine sau maltodextrine). Compoziţiile mai pot cuprinde una sau mai multe alchil zaharide. Alchil zaharidele preferate includ esteri de zaharoză, cum ar fi monolauratul de zaharoză.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2007306.0A GB202007306D0 (en) | 2020-05-18 | 2020-05-18 | New pharmaceutical composition |
GBGB2009905.7A GB202009905D0 (en) | 2020-06-29 | 2020-06-29 | New pharmaceutical composition |
GBGB2018901.5A GB202018901D0 (en) | 2020-12-01 | 2020-12-01 | New pharmaceutical composition |
PCT/GB2021/051191 WO2021234366A1 (en) | 2020-05-18 | 2021-05-18 | New pharmaceutical composition for drug delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3962455T2 true MD3962455T2 (ro) | 2022-12-31 |
Family
ID=76138084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20220282T MD3962455T2 (ro) | 2020-05-18 | 2021-05-18 | Compoziție farmaceutică nouă pentru livrare de medicamente |
Country Status (24)
Country | Link |
---|---|
US (2) | US11737980B2 (ro) |
EP (2) | EP3962455B1 (ro) |
JP (1) | JP2023526098A (ro) |
KR (1) | KR20230012502A (ro) |
CN (1) | CN115666513A (ro) |
AU (1) | AU2021276611A1 (ro) |
BR (1) | BR112022023307A2 (ro) |
CA (1) | CA3178769A1 (ro) |
CL (1) | CL2022002979A1 (ro) |
CO (1) | CO2022015183A2 (ro) |
DK (1) | DK3962455T3 (ro) |
ES (1) | ES2929818T3 (ro) |
HR (1) | HRP20221361T1 (ro) |
HU (1) | HUE060573T2 (ro) |
IL (1) | IL297658A (ro) |
LT (1) | LT3962455T (ro) |
MD (1) | MD3962455T2 (ro) |
MX (1) | MX2022014216A (ro) |
PE (1) | PE20230382A1 (ro) |
PL (1) | PL3962455T3 (ro) |
PT (1) | PT3962455T (ro) |
RS (1) | RS63725B1 (ro) |
SI (1) | SI3962455T1 (ro) |
WO (1) | WO2021234366A1 (ro) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023094818A1 (en) * | 2021-11-25 | 2023-06-01 | Orexo Ab | Pharmaceutical composition comprising biopharmaceutical drug compounds |
GB202117016D0 (en) * | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
AR127780A1 (es) | 2021-11-25 | 2024-02-28 | Orexo Ab | Nueva composición farmacéutica que comprende adrenalina |
WO2023187393A1 (en) | 2022-03-31 | 2023-10-05 | Hovione Scientia Limited | Inhalation composite and carrier based formulation combination |
AU2023262714A1 (en) * | 2022-04-29 | 2024-03-07 | Pentide Therapeutics Limited | Pharmaceutical compositions of semaglutide and the methods of use thereof |
WO2024031148A1 (en) * | 2022-08-11 | 2024-02-15 | De Motu Cordis Pty Ltd | Inhalable epinephrine formulation |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE759520A (fr) | 1969-11-28 | 1971-04-30 | Aspro Nicholas Ltd | Compositions d'aspirine |
US5082669A (en) | 1989-07-20 | 1992-01-21 | Dainippon Pharmaceutical Co., Ltd. | Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked |
SE8904296D0 (sv) | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
NZ270049A (en) | 1993-12-06 | 1995-10-26 | Takeda Chemical Industries Ltd | Composition comprising a water insoluble or slightly water soluble compound and a cyclodextrin-carboxylic acid |
CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
DE19518810A1 (de) | 1995-05-26 | 1996-11-28 | Bayer Ag | Nasal-Applikator |
CN1106888C (zh) | 1998-03-10 | 2003-04-30 | 瓦卢瓦股份有限公司 | 容器、容器的灌注方法及容器中流体制品的分配装置 |
RS49890B (sr) * | 1998-07-08 | 2008-08-07 | Kirin-Amgen Inc., | Preparat u formi praška koji sadrži medicinsko sredstvo velike molekulske težine za primenu preko sluzokože |
JP2000178184A (ja) | 1998-12-17 | 2000-06-27 | Lion Corp | 粒状組成物、錠剤及び粒状組成物の製造方法 |
GB9908921D0 (en) | 1999-04-19 | 1999-06-16 | Britannia Pharmaceuticals Ltd | Spray dispenser for opiod antagonists |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
GB0003782D0 (en) | 2000-02-17 | 2000-04-05 | Dumex Ltd As | Process |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
KR20010107754A (ko) | 2000-05-26 | 2001-12-07 | 민경윤 | 경구투여용 속용정의 제조 방법 |
FR2817847B1 (fr) | 2000-12-08 | 2003-03-28 | Tebro | Dispositif de distribution de produit fluide ou pulverulent |
IN192750B (ro) | 2000-12-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
LU90825B1 (en) | 2001-09-06 | 2003-03-07 | Iee Sarl | Method for the determination of one or more parameters of a seat passenger |
ITMI20012174A1 (it) | 2001-10-18 | 2003-04-18 | Univ Parma | Polvere per somministrazione nasale di farmaci |
FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
GB0201367D0 (en) | 2002-01-22 | 2002-03-13 | Ml Lab Plc | Composition |
AU2006207868A1 (en) | 2002-03-20 | 2006-09-28 | Alkermes, Inc. | Method and apparatus for producing dry particles |
PT1531794T (pt) | 2002-06-28 | 2017-09-14 | Civitas Therapeutics Inc | Epinefrina inalável |
AU2003296954A1 (en) | 2002-12-13 | 2004-07-09 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
EP1599186B1 (en) | 2003-02-24 | 2013-04-10 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US7749533B2 (en) | 2003-05-07 | 2010-07-06 | Akina, Inc. | Highly plastic granules for making fast melting tablets |
WO2004112702A2 (en) | 2003-06-13 | 2004-12-29 | Advanced Inhalation Research, Inc. | Low dose pharmaceutical powders for inhalation |
CN100471497C (zh) | 2003-06-25 | 2009-03-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 盐酸纳洛酮鼻粉剂 |
EP1671667A4 (en) | 2003-10-09 | 2013-05-01 | Shin Nippon Biomedical Lab Ltd | NASAL PULVERULENT DRUG DELIVERY DEVICE |
WO2005044186A2 (en) | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same |
CN1640402A (zh) | 2004-01-02 | 2005-07-20 | 广东奇方药业有限公司 | 一种稳定的纳洛酮粉针剂 |
IL159729A0 (en) | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
CN1615867A (zh) | 2004-10-22 | 2005-05-18 | 北京阳光润禾科技有限公司 | 注射用盐酸纳洛酮冻干粉针制剂 |
WO2006101536A1 (en) | 2004-11-04 | 2006-09-28 | Akina, Inc. | Fast-melting tablets having taste-masking and sustained release properties |
CN1781479B (zh) | 2004-12-02 | 2010-06-30 | 和记黄埔医药企业有限公司 | 一种马蔺子素分散体系及其制备方法 |
RU2007133503A (ru) | 2005-02-10 | 2009-03-20 | Орексо Аб (Se) | Новые фармацевтические композиции, пригодные для трансмукозального введения лекарств |
KR101233235B1 (ko) | 2005-08-26 | 2013-02-15 | 에스케이케미칼주식회사 | 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법 |
US20070202163A1 (en) | 2005-09-09 | 2007-08-30 | Mutasem Rawas-Qalaji | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
CN1939358A (zh) | 2005-09-30 | 2007-04-04 | 江西本草天工科技有限责任公司 | 肿节风分散片 |
CN1813739A (zh) | 2005-11-25 | 2006-08-09 | 王颖 | 一种注射用盐酸纳美芬冻干粉针制剂 |
AU2007208998A1 (en) | 2006-01-27 | 2007-08-02 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | A method of producing porous microparticles |
WO2007096906A2 (en) | 2006-02-27 | 2007-08-30 | Panacea Biotec Ltd. | Novel buccoadhesive compositions and process of preparation thereof |
WO2007108010A2 (en) | 2006-03-21 | 2007-09-27 | Jubilant Organosys Limited | Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate |
AU2007232098A1 (en) | 2006-03-31 | 2007-10-11 | Rubicon Research Private Limited | Directly compressible composite for orally disintegrating tablets |
WO2008033023A2 (en) | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture |
US20080269347A1 (en) | 2006-09-28 | 2008-10-30 | Azopharma, Inc. | Epinephrine formulations |
WO2008127746A1 (en) | 2007-01-10 | 2008-10-23 | Board Of Regents The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
WO2009040595A1 (en) | 2007-09-28 | 2009-04-02 | Wockhardt Research Centre | Multi-dose pharmaceutical composition of analgesic for nasal administration |
CA2718255C (en) | 2008-03-11 | 2016-08-23 | Aska Pharmaceutical Co., Ltd. | Solid dispersion and pharmaceutical composition of the same, and production processes thereof |
US20090246256A1 (en) | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Compositions and Methods for Transmucosal Delivery of Lofexidine |
US20090264530A1 (en) | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
TR201802619T4 (tr) * | 2009-05-20 | 2018-03-21 | Aeras | Kararlı, sprey ile kurutulmuş, immunojen, viral bileşimler. |
US9463161B2 (en) * | 2009-05-29 | 2016-10-11 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
EP2266563A1 (en) | 2009-06-11 | 2010-12-29 | Charité-Universitätsmedizin Berlin (Charité) | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
US20110097401A1 (en) | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
WO2011013003A2 (en) | 2009-07-31 | 2011-02-03 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
NZ599344A (en) | 2009-09-25 | 2015-02-27 | Reddy’S Lab Ltd Dr | Formulations comprising triptan compounds |
EP2608775A2 (en) | 2010-08-27 | 2013-07-03 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
WO2012030664A1 (en) * | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
RU2589842C2 (ru) | 2010-10-01 | 2016-07-10 | Сипла Лимитед | Фармацевтическая композиция |
CN108969490A (zh) | 2010-12-02 | 2018-12-11 | 艾戴尔医药公司 | 快速分散颗粒、口腔崩解片以及方法 |
MX2018007514A (es) | 2011-02-18 | 2022-10-21 | Biolingus Ip Llc | Proceso para preparar productos que comprenden activos estabilizados y composiciones que los comprenden. |
MX354249B (es) | 2011-05-13 | 2018-02-20 | Euro Celtique Sa | Formas de dosificación farmacéuticas intranasales que comprenden naloxona. |
CN104203217B (zh) | 2012-05-11 | 2017-02-15 | 株式会社活效制药 | 有机化合物纳米粉体的制造方法 |
CA3169368A1 (en) * | 2012-06-15 | 2014-01-09 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
US9789071B2 (en) * | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
CN104470569B (zh) | 2012-06-28 | 2018-04-27 | 美国政府(由卫生和人类服务部的部长所代表) | 用于疫苗和其它治疗试剂的鼻干粉递送系统 |
FR3007992B1 (fr) | 2013-07-05 | 2018-01-26 | Aptar France Sas | Dispositif de distribution de produit fluide ou pulverulent. |
AU2014315459A1 (en) | 2013-09-03 | 2016-04-07 | G2B Pharma Inc. | Intranasal formulation for the treatment of cardiopulmonary resuscitation (CPR), cardiac life support (CLS), anaphylaxis and/or anaphylactoid reactions |
EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
EP3082817A4 (en) | 2013-12-18 | 2017-06-21 | Aegis Therapeutics, LLC | Compositions for drug administration |
WO2015095644A1 (en) | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
EP4218742A1 (en) * | 2014-04-04 | 2023-08-02 | AI Therapeutics, Inc. | An inhalable rapamycin formulation for treating age-related conditions |
US20190008759A1 (en) | 2014-07-03 | 2019-01-10 | Darren Rubin | Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body |
US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
EP3174534A1 (en) | 2014-08-01 | 2017-06-07 | KRKA, d.d., Novo mesto | Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters |
MY191712A (en) | 2014-10-08 | 2022-07-09 | Zambon Spa | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation |
WO2016074800A1 (en) | 2014-11-14 | 2016-05-19 | Asoltech S.R.L. | Composition based on coq10 |
EP3025705B8 (en) | 2014-11-25 | 2018-11-28 | Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi | Stable ivabradine formulations |
CN104547220A (zh) | 2014-12-30 | 2015-04-29 | 陈宏� | 一种治疗儿童视觉疲劳的中药组合物及其制剂 |
US10166197B2 (en) | 2015-02-13 | 2019-01-01 | St. John's University | Sugar ester nanoparticle stabilizers |
HUE049413T2 (hu) | 2015-02-17 | 2020-09-28 | Lilly Co Eli | Nazális porkészítmény hipoglikémia kezelésére |
US20170189352A1 (en) | 2015-03-13 | 2017-07-06 | Par Pharmaceutical, Inc. | Epinephrine formulations |
CA2981991A1 (en) | 2015-04-08 | 2016-10-13 | Chang-Chun LING | Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof |
EP3288591A1 (en) | 2015-05-01 | 2018-03-07 | Civitas Therapeutics, Inc. | Zolmitriptan powders for pulmonary delivery |
US10039710B2 (en) | 2015-09-18 | 2018-08-07 | Insys Development Company, Inc. | Epinephrine spray formulations |
AU2017210319A1 (en) | 2016-01-20 | 2018-08-23 | Flurry Powders, Llc | Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation |
ITUB20161027A1 (it) * | 2016-02-24 | 2017-08-24 | Altergon Sa | Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio |
BR112018068855A2 (pt) | 2016-03-16 | 2019-01-22 | Omegatri As | pós e comprimidos que compreendem os derivados de ácido graxos de omega-3 e os métodos de sua produção |
US20170312226A1 (en) | 2016-04-28 | 2017-11-02 | Ascent Pharmaceuticals, Inc. | Pharmaceutical dosage forms |
EP3463375A1 (en) | 2016-06-03 | 2019-04-10 | M Et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
WO2017218918A1 (en) | 2016-06-17 | 2017-12-21 | Ys Pharmtech | Stabilization of epinephrine formulations |
MX2019001313A (es) | 2016-08-05 | 2019-09-26 | Shin Nippon Biomedical Laboratories Ltd | Composiciones farmaceuticas. |
CA3035822A1 (en) | 2016-09-28 | 2018-04-05 | Chrono Therapeutics Inc. | Transdermal drug delivery device for delivering opioids |
WO2018064672A1 (en) | 2016-09-30 | 2018-04-05 | Opiant Pharmaceuticals, Inc. | Treatment with intranasal naloxone |
US20180092839A1 (en) | 2016-10-03 | 2018-04-05 | Lance L. Gooberman | Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders |
EP3538189A4 (en) | 2016-11-09 | 2020-04-22 | Opiant Pharmaceuticals, Inc. | COMPOSITIONS, DEVICES AND METHODS FOR TREATING OPIOID RECEPTOR-MEDIATED STATES |
CN110139651A (zh) | 2016-11-18 | 2019-08-16 | 欧邦特制药公司 | 用于治疗阿片样物质过量的组合物和方法 |
WO2018148382A1 (en) | 2017-02-10 | 2018-08-16 | Mucodel Pharma Llc | Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery |
JOP20190241B1 (ar) | 2017-04-17 | 2023-09-17 | Hikma Pharmaceuticals Usa Inc | مستحضرات رذاذ إبينيفرين |
EP3668490A4 (en) | 2017-08-20 | 2021-06-09 | Formulex Pharma Innovations Ltd. | DRY POWDER COMPOSITIONS FOR INTRANASAL ADMINISTRATION |
US20180193332A1 (en) | 2017-10-09 | 2018-07-12 | Adapt Pharma Operations Limited | Low-temperature stable opioid antagonist solutions |
WO2019139865A1 (en) | 2018-01-10 | 2019-07-18 | Insys Development Company. Inc. | Methods of stabilizing epinephrine |
WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
WO2019241401A1 (en) | 2018-06-13 | 2019-12-19 | Insys Development Company, Inc. | Epinephrine spray formulations |
EA202091615A1 (ru) | 2018-12-21 | 2021-03-05 | Аегис Терапьютикс, Ллс | Интраназальные составы на основе эпинефрина и способы лечения заболевания |
US20230014352A1 (en) | 2019-03-29 | 2023-01-19 | The Regents Of The University Of California | Inhaled statins as bronchodilators to improve lung function in respiratory diseases |
US10729687B1 (en) | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
US10653690B1 (en) | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
US11400045B2 (en) | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
-
2021
- 2021-05-18 CA CA3178769A patent/CA3178769A1/en active Pending
- 2021-05-18 HU HUE21728101A patent/HUE060573T2/hu unknown
- 2021-05-18 PE PE2022002543A patent/PE20230382A1/es unknown
- 2021-05-18 MD MDE20220282T patent/MD3962455T2/ro unknown
- 2021-05-18 LT LTEPPCT/GB2021/051191T patent/LT3962455T/lt unknown
- 2021-05-18 PT PT217281013T patent/PT3962455T/pt unknown
- 2021-05-18 BR BR112022023307A patent/BR112022023307A2/pt unknown
- 2021-05-18 EP EP21728101.3A patent/EP3962455B1/en active Active
- 2021-05-18 JP JP2022570692A patent/JP2023526098A/ja active Pending
- 2021-05-18 ES ES21728101T patent/ES2929818T3/es active Active
- 2021-05-18 IL IL297658A patent/IL297658A/en unknown
- 2021-05-18 SI SI202130007T patent/SI3962455T1/sl unknown
- 2021-05-18 PL PL21728101.3T patent/PL3962455T3/pl unknown
- 2021-05-18 DK DK21728101.3T patent/DK3962455T3/da active
- 2021-05-18 MX MX2022014216A patent/MX2022014216A/es unknown
- 2021-05-18 KR KR1020227040261A patent/KR20230012502A/ko unknown
- 2021-05-18 HR HRP20221361TT patent/HRP20221361T1/hr unknown
- 2021-05-18 RS RS20221016A patent/RS63725B1/sr unknown
- 2021-05-18 WO PCT/GB2021/051191 patent/WO2021234366A1/en active Application Filing
- 2021-05-18 EP EP22191078.9A patent/EP4154866A1/en active Pending
- 2021-05-18 AU AU2021276611A patent/AU2021276611A1/en active Pending
- 2021-05-18 CN CN202180036365.8A patent/CN115666513A/zh active Pending
- 2021-12-02 US US17/540,929 patent/US11737980B2/en active Active
-
2022
- 2022-10-25 CO CONC2022/0015183A patent/CO2022015183A2/es unknown
- 2022-10-26 CL CL2022002979A patent/CL2022002979A1/es unknown
-
2023
- 2023-06-30 US US18/345,770 patent/US20240024244A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3178769A1 (en) | 2021-11-25 |
DK3962455T3 (en) | 2022-10-24 |
EP3962455A1 (en) | 2022-03-09 |
JP2023526098A (ja) | 2023-06-20 |
US11737980B2 (en) | 2023-08-29 |
KR20230012502A (ko) | 2023-01-26 |
PL3962455T3 (pl) | 2023-01-16 |
WO2021234366A1 (en) | 2021-11-25 |
CO2022015183A2 (es) | 2023-02-27 |
LT3962455T (lt) | 2022-10-25 |
ES2929818T3 (es) | 2022-12-02 |
EP4154866A1 (en) | 2023-03-29 |
CL2022002979A1 (es) | 2023-05-12 |
PE20230382A1 (es) | 2023-03-06 |
PT3962455T (pt) | 2022-10-13 |
EP3962455B1 (en) | 2022-08-31 |
RS63725B1 (sr) | 2022-12-30 |
CN115666513A (zh) | 2023-01-31 |
AU2021276611A1 (en) | 2022-12-15 |
SI3962455T1 (sl) | 2022-11-30 |
US20240024244A1 (en) | 2024-01-25 |
HUE060573T2 (hu) | 2023-03-28 |
BR112022023307A2 (pt) | 2022-12-20 |
IL297658A (en) | 2022-12-01 |
MX2022014216A (es) | 2022-12-07 |
HRP20221361T1 (hr) | 2023-01-06 |
US20220087938A1 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3962455T2 (ro) | Compoziție farmaceutică nouă pentru livrare de medicamente | |
BE1005018A3 (fr) | Medicaments qui contiennent, comme substance active, des acides carboxyliques contenant du soufre, ainsi que leur utilisation pour lutter contre des retrovirus. | |
US10493081B2 (en) | Methods for treatment of diseases | |
AR028504A2 (es) | Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial | |
CZ187097A3 (cs) | Farmaceutický prostředek | |
MXPA01008611A (es) | Compuestos y composiciones para suministrar agentes activos. | |
GEP20033131B (en) | Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity | |
JP2019533016A5 (ro) | ||
CO2022000254A2 (es) | Composición farmacéutica para suministro nasal | |
ATE387430T1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
NO20045140L (no) | Blandinger og fremgangsmate for transmukosal legemiddelavlevering og kryobeskyttelse | |
KR20060124608A (ko) | 석면-관련된 질환 또는 장애를 치료 및 관리하기 위하여면역조절성 화합물을 사용하는 방법 및 이 물질을 포함하는조성물 | |
BG66095B1 (bg) | Хидрофилен състав с контролирано освобождаване съдържащ прежелатинирано нишесте в препарат | |
IL195055A (en) | Carboxylic acid components and compounds for transporting active carriers | |
JP2013028648A (ja) | ホモハリングトニンを含むセファロタキシンの製剤および投与方法 | |
AU3492100A (en) | Oxadiazole compounds and compositions for delivering active agents | |
MXPA02003440A (es) | Composiciones farmaceuticas novedosas. | |
NZ596064A (en) | Fixed dose drug combination formulations | |
AR030281A1 (es) | Quimioterapia de combinacion | |
US6387392B1 (en) | Intraoral adhesive preparation | |
RU2005131868A (ru) | Фармацевтическая композиция, фармацевтическая комбинация (варианты) и способы их применения | |
JP7314986B2 (ja) | 眼科用製品及び粘度低下抑制方法 | |
Horwitz | Novel therapies for cutaneous T-cell lymphomas | |
TR200101928T2 (tr) | Geliştirilmiş kararlılığa sahip bileşimler | |
KR20140144213A (ko) | 3제를 조합한 신규 항종양제 |